Compare Cardinal Health Inc (CAH) vs D R Horton Inc (DHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs D R Horton Inc — how do they compare? Cardinal Health Inc trades at $237.11 (market cap $55.88B), while D R Horton Inc trades at $146.67 (market cap $42.18B). The key difference: Cardinal Health Inc is the larger of the two by market cap, and D R Horton Inc pays the higher dividend (1.19%). Which is the better fit depends on your goals.
| CAH | DHI | |
|---|---|---|
Market Cap | $55.88B | $42.18B |
Sector | Health | Consumer Cyclical |
52-Week High | $240.26 | $184.04 |
52-Week Low | $146.04 | $132.53 |
Enterprise Value | $59.91B | $47.28B |
Dividend Yield | 0.86% | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $237.18, up 0.33% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%. Positive sentiment is driven by strong Q4 2026 results and optimistic fiscal 2027 guidance highlighted by Reuters on August 11, 2026.
Outlook remains favorable with analyst consensus price target of $266.43 implying 12% upside. Key opportunities include pharmaceutical segment strength and dividend payments, while risks involve high debt levels and thin profit margins. The bullish analyst stance (54.55% buy ratings) supports growth potential, but investors should monitor cash flow volatility and competitive pressures.
DHI trades at $146.66, down 2.93% on the day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, including Q2 2026 EPS of $3.20 versus $3.02 expected. However, revenue and net income have trended lower from 2023 peaks, with 2025 revenue at $34.25B and net income at $3.59B. The company maintains a reasonable valuation with a P/E of 14.37 and recently declared a $0.45 dividend payable in August 2026.
The outlook is mixed; strong execution and cash returns support the stock, but lowered guidance and margin pressure from elevated mortgage rates pose headwinds. Analyst consensus is nearly evenly split between Buy and Hold, with a $153 price target suggesting modest upside. Key risks include persistent demand softness in housing and competitive disruption from new entrants like Boxabl.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →
